YOLFTbeta
AIM ImmunoTech Inc

AIM ImmunoTech Inc

AIM · AMEX · Healthcare / Biotechnology

0.1436USD-0.01 (-3.36%)

Price History

Full chart

Market Stats

Previous Close0.1486
Open0.15
Day Range0.1419 – 0.1547
52-Week Range0.1874 – 2.88
Volume475.97K
Market Cap7.45M
P/E (TTM)0.00
Forward P/E2.01
EPS-0.71
Dividend Yield0.00%
Beta1.19
50-Day Avg0.2414
200-Day Avg0.6324

About

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Thomas K. Equels Esq., J.D., M.S.
  • Employees19
  • Headquarters2117 SW Highway 484, Ocala, FL, United States, 34473, USA
  • Websitehttps://aimimmuno.com

Leadership

  • Mr. Thomas K. Equels Esq., J.D., M.S.Executive Vice Chairman, CEO & President · b. 1953
  • Mr. Robert Dickey IV, B.A., M.B.A.Chief Financial Officer · b. 1956
  • Mr. Peter W. Rodino III, Esq., J.D.COO, Executive Director of Governmental Relations, General Counsel & Secretary · b. 1951
  • Ann Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations Coordinator
  • Dr. Christopher Nicodemus FACP, M.D.Member of Scientific Advisory Board & Consulting Science Officer

Financials

Income Statement

Currency: USD1995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.00M100.00K300.00K400.00K700.00K788.00K390.00K341.00K657.00K1.23M1.08M933.00K1.06M265.00K111.00K135.00K161.00K213.00K150.00K197.00K133.00K92.00K437.00K367.00K140.00K163.00K135.00K141.00K202.00K170.00K88.00K
Growth (%)--96.67%+200.00%+33.33%+75.00%+12.57%-50.51%-12.56%+92.67%+87.06%-11.88%-13.85%+13.50%-74.98%-58.11%+21.62%+19.26%+32.30%-29.58%+31.33%-32.49%-30.83%+375.00%-16.02%-61.85%+16.43%-17.18%+4.44%+43.26%-15.84%-48.24%
Cost of Revenue-300.00K-100.00K-200.00K-300.00K-300.00K-487.00K--502.00K2.11M391.00K1.27M930.00K798.00K584.00K1.34M1.04M1.99M1.23M1.25M1.60M1.11M1.18M884.00K893.00K806.00K850.00K-424.00K42.00K31.00K338.00K
Gross Profit3.30M200.00K500.00K700.00K1.00M1.27M390.00K341.00K155.00K-883.00K692.00K-342.00K129.00K-533.00K-473.00K-1.21M-882.00K-1.78M-1.08M-1.05M-1.47M-1.02M-746.00K-517.00K-753.00K-643.00K-715.00K141.00K160.00K139.00K-250.00K
Gross Margin110.00%200.00%166.67%175.00%142.86%161.80%100.00%100.00%23.59%-71.85%63.90%-36.66%12.18%-201.13%-426.13%-893.33%-547.83%-833.80%-722.67%-535.03%-1101.50%-1104.35%-170.71%-140.87%-537.86%-394.48%-529.63%100.00%79.21%81.76%-284.09%
Operating Expense4.30M5.00M6.90M7.90M13.78M10.32M9.19M6.96M7.41M10.01M10.61M18.35M18.89M12.28M12.79M15.18M13.41M18.56M16.08M18.05M15.19M12.79M10.67M10.98M11.69M14.51M18.12M20.06M32.08M19.91M10.28M
Operating Income-1.00M-4.80M-6.40M-7.20M-12.78M-9.04M-8.80M-6.62M-7.25M-10.89M-9.91M-18.69M-18.76M-12.81M-13.26M-16.39M-14.29M-20.34M-17.17M-19.10M-16.65M-13.80M-11.42M-11.50M-12.44M-15.15M-18.84M-19.92M-31.92M-19.77M-10.53M
Operating Margin-33.33%-4800.00%-2133.33%-1800.00%-1825.71%-1147.59%-2256.92%-1941.35%-1103.81%-886.00%-915.51%-2003.64%-1771.77%-4834.34%-11949.55%-12138.52%-8878.88%-9549.30%-11444.67%-9694.92%-12518.80%-15004.35%-2612.36%-3132.43%-8887.86%-9295.71%-13954.07%-14129.65%-15800.00%-11630.59%-11961.36%
EBITDA-700.00K-4.70M-6.20M-6.90M-12.46M-8.56M-8.28M-6.32M2.07M-10.77M-8.93M-17.77M-17.31M-12.10M-12.46M-12.35M-8.34M-16.65M-15.52M-16.74M-14.25M-6.33M-7.12M-8.40M-8.15M-12.99M-18.29M-19.19M-28.72M-16.49M-12.94M
EBITDA Margin-23.33%-4700.00%-2066.67%-1724.75%-1780.14%-1085.79%-2122.56%-1854.25%314.46%-876.57%-824.56%-1904.39%-1634.28%-4564.15%-11222.52%-9144.44%-5182.61%-7815.49%-10345.33%-8498.98%-10715.79%-6883.70%-1628.38%-2290.19%-5820.00%-7972.39%-13544.44%-13609.22%-14219.80%-9699.41%-14700.00%
Net Income-1.80M-4.60M-6.10M-7.30M-12.30M-8.55M-9.08M-7.42M-13.99M-23.40M-12.45M-19.40M-18.14M-12.22M-13.44M-13.14M-9.02M-17.35M-16.23M-17.45M-15.23M-7.50M-8.26M-9.81M-9.40M-14.40M-19.13M-19.45M-28.96M-17.32M-13.96M
Net Income Margin-60.00%-4600.00%-2033.33%-1825.00%-1756.86%-1085.28%-2328.97%-2177.13%-2129.83%-1903.82%-1149.22%-2079.21%-1712.84%-4610.94%-12106.31%-9730.37%-5599.38%-8147.42%-10816.67%-8857.87%-11451.13%-8154.35%-1889.93%-2673.84%-6717.14%-8834.36%-14168.15%-13790.78%-14337.62%-10188.24%-15861.36%
R&D-1.90M3.20M4.60M4.70M6.14M5.78M4.95M3.15M3.84M5.14M10.13M10.44M5.80M7.00M7.61M6.72M9.51M8.36M8.99M8.04M5.11M4.10M4.78M4.65M5.72M7.67M6.99M10.93M6.20M3.92M
R&D as % of Total Revenue-1900.00%1066.67%1150.00%671.43%778.68%1482.05%1450.44%479.45%312.61%474.98%1085.42%986.21%2188.68%6301.80%5639.26%4175.16%4463.85%5573.33%4562.44%6043.61%5551.09%937.76%1301.91%3322.14%3509.20%5682.96%4957.45%5408.42%3645.29%4459.09%
Interest Expense---------12.19M3.12M1.26M396.00K592.00K241.00K11.00K41.00K24.00K16.00K11.00K3.00K129.00K139.00K502.00K427.00K672.00K67.00K478.00K0585.00K812.00K
Interest Expense % of Total Revenue---------991.46%288.18%134.94%37.39%223.40%217.12%8.15%25.47%11.27%10.67%5.58%2.26%140.22%31.81%136.78%305.00%412.27%49.63%339.01%0.00%344.12%922.73%

Balance Sheet

Currency: USD1995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.70M7.00M11.50M16.30M14.20M13.07M12.04M6.04M13.40M25.17M24.67M31.43M23.14M13.21M64.99M51.68M43.51M57.70M31.87M29.44M22.80M18.87M14.21M13.85M20.22M111.02M57.70M40.49M19.38M8.61M5.78M
Total Liabilities8.30M1.10M800.00K1.10M1.50M1.50M1.27M1.46M4.16M5.09M4.83M6.68M2.19M1.67M2.62M5.73M5.55M13.00M2.57M4.44M2.43M3.38M5.50M8.67M7.31M49.73M820.00K2.02M9.15M9.93M15.56M
Total Equity4.40M5.90M10.70M15.20M12.70M11.57M10.76M3.63M9.25M20.08M18.63M24.75M20.95M11.54M58.70M45.95M37.97M44.70M29.30M25.00M20.37M15.50M8.70M5.17M12.91M61.29M56.88M38.47M10.23M-1.32M-9.78M
Cash11.30M5.30M9.00M12.00M6.40M3.72M3.11M2.26M3.76M8.81M3.83M3.65M11.47M6.12M58.07M2.92M3.10M2.21M803.00K2.16M2.12M2.41M1.41M299.00K1.47M38.50M32.09M27.05M5.44M1.70M931.00K
Total Debt4.90M-------2.06M2.19M3.22M3.87M---157.00K2.22M101.00K56.00K22.00K1.00K-1.83M5.92M6.38M2.29M149.00K837.00K718.00K2.94M4.90M
Net Debt-6.40M-5.30M-9.00M-12.00M-6.40M-3.72M-3.11M-2.26M-1.71M-5.26M-610.00K225.00K-11.47M-6.12M-58.07M-2.76M-880.00K-2.11M-747.00K-2.13M-2.11M-2.41M423.00K5.63M4.91M-36.22M-31.94M-26.22M-4.72M1.24M3.96M

Cash Flow

Currency: USD1995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.90M-6.10M-4.60M-5.90M-7.00M-8.07M-7.28M-6.41M-7.02M-7.24M-7.24M-13.75M-15.11M-9.36M-9.30M-11.89M-10.10M-13.14M-16.83M-13.92M-16.05M-7.38M-7.94M-10.64M-9.07M-10.37M-13.96M-16.11M-21.27M-14.89M-10.96M
Investing Cash Flow-100.00K-500.00K-1.30M-2.10M-1.40M-3.25M-920.00K4.60M-1.79M-6.80M-5.78M-7.21M13.96M3.74M-574.00K-43.52M8.65M-16.07M22.27M2.49M6.35M2.92M2.73M92.00K-6.15M-9.16M-631.00K10.99M-832.00K4.71M1.85M
Financing Cash Flow13.30M600.00K9.70M11.00M2.80M8.64M7.59M961.00K10.32M19.09M8.03M20.77M8.98M270.00K61.82M250.00K1.62M28.31M-6.85M12.78M9.66M4.76M4.21M9.44M16.39M56.56M8.19M80.00K485.00K6.44M10.39M
Capital Expenditure0100.00K0200.00K300.00K171.00K0019.00K150.00K1.17M1.42M423.00K215.00K574.00K1.07M2.04M5.97M1.14M762.00K490.00K454.00K69.00K127.00K365.00K595.00K41.00K271.00K585.00K18.00K378.00K
Free Cash Flow-1.90M-6.20M-4.60M-6.10M-7.30M-8.24M-7.28M-6.41M-7.04M-7.39M-8.41M-15.17M-15.54M-9.57M-9.87M-12.95M-12.13M-19.10M-17.97M-14.68M-16.54M-7.83M-8.01M-10.77M-9.43M-10.96M-14.01M-16.38M-21.85M-14.91M-11.34M
FCF to OCF100.00%101.64%100.00%103.39%104.29%102.12%100.00%100.00%100.27%102.07%116.17%110.36%102.80%102.30%106.17%108.97%120.17%145.42%106.77%105.47%103.05%106.15%100.87%101.19%104.03%105.74%100.29%101.68%102.75%100.12%103.45%

Earnings

Report DateMar 31, 1998Jun 30, 1998Sep 30, 1998Mar 31, 1999Jun 30, 1999Sep 30, 1999Dec 31, 1999Mar 31, 2000Jun 30, 2000Sep 30, 2000Dec 31, 2000Mar 31, 2001Jun 30, 2001Sep 30, 2001Dec 31, 2001Mar 31, 2002Jun 30, 2002Nov 15, 2002Dec 31, 2002May 20, 2003Aug 20, 2003Nov 18, 2003Mar 15, 2004May 14, 2004Aug 11, 2004Nov 10, 2004Mar 16, 2005May 11, 2005Aug 10, 2005Nov 10, 2005Mar 16, 2006Aug 14, 2006Nov 7, 2006Mar 19, 2007May 11, 2007Aug 9, 2007Nov 8, 2007Mar 18, 2008May 13, 2008Aug 12, 2008Nov 10, 2008Mar 16, 2009May 12, 2009Aug 10, 2009Nov 9, 2009Mar 15, 2010May 7, 2010Aug 6, 2010Nov 8, 2010Mar 29, 2011May 6, 2011Aug 5, 2011Nov 9, 2011Mar 14, 2012May 7, 2012Aug 8, 2012Nov 2, 2012Mar 18, 2013May 8, 2013Aug 9, 2013Nov 8, 2013Mar 14, 2014May 9, 2014Aug 8, 2014Nov 7, 2014Mar 20, 2015May 12, 2015Aug 13, 2015Nov 9, 2015Mar 29, 2016May 16, 2016Aug 15, 2016Nov 14, 2016May 15, 2017Aug 14, 2017Nov 14, 2017Mar 30, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Mar 28, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Mar 30, 2020May 18, 2020Aug 14, 2020Nov 12, 2020Mar 31, 2021May 17, 2021Aug 16, 2021Nov 15, 2021May 13, 2022Aug 15, 2022Nov 14, 2022Mar 31, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Dec 31, 2023May 15, 2024Aug 14, 2024Nov 14, 2024Mar 27, 2025May 15, 2025Aug 14, 2025Nov 17, 2025Dec 31, 2025May 15, 2026Aug 7, 2026Nov 16, 2026
EPS Estimate------------------3692.31----------------31.68-4219.78-3692.31-2637.36-527.47------16.37-15.31-10.03-15.31-15.31-1582.42--1265.93-1371.43-1265.93-1371.43--1213.19-1213.19--1054.95-1160.44-1160.44-15.84-1002.20-1397.80-1107.69--1054.95-------------263.74-0.07-219.78-169.83-96.90-38.30-0.22-10.99-8.33-0.07-8.66-8.33-7.99-8.99-7.66-9.32-11.66-0.11-9.99-10.99-0.15-10.99-12.32-8.66-0.09-7.99-7.99-0.98-0.94-0.37-0.12-0.09
EPS Actual-3709.07-3895.52-3853.85-5822.16-5798.05-3765.37-3692.31-3681.75-3742.37-3690.84-4426.88-4366.56-4104.62-3706.16-3549.13-2447.23-4329.99-3164.84-2319.61-2632.99-5805.16-7765.16-5802.20-10430.52-7161.00-7853.47-2637.36-3783.04-4001.73-2968.33-3692.31-4185.46-3209.34-36.96-3692.31-4219.78-4219.78-2637.36-2260.13-1995.81-2404.49-1991.48-2039.56-21.12-10.56-10.56-15.84-15.84-1054.95-1054.95-527.47-1054.95-1292.31-1582.42-896.55-1054.95-2637.36-1582.42-1054.95-1582.42-1582.42-10.56-1054.95-1582.42-1054.95-1152.14-1054.95-1082.20-813.69-669.07-4.62-2.77-5.77-4.90-3.53-1.83-2.67-3.29-2.38-307.69-1.32-276.48-106.89-112.89-13.99-0.22-11.71-7.99-0.09-7.99-7.19-8.14-6.00-9.11-12.51-9.31-0.08-10.61-16.15-0.28-11.99-3.00-6.88-10.00-4.99-3.68-1.57-0.44-0.69-0.43-
Surprise-----------------14.29%----------------16.67%12.50%-14.29%-60.00%-400.00%------29.02%31.03%-5.28%-3.46%-3.46%33.33%-58.33%23.08%-2.08%-15.38%-13.04%-117.39%-0.00%-36.36%-36.36%33.33%-5.26%-13.21%4.76%-0.00%-------------16.66%-1785.71%-25.80%37.06%-16.50%63.47%0.00%-6.55%4.08%-28.57%7.74%13.69%-1.88%33.26%-18.93%-34.23%20.15%27.27%-6.21%-46.95%-88.13%-9.10%75.65%20.55%-11011.11%37.55%53.94%-60.20%53.15%-86.49%-258.33%-
Timing-----------------Pre-market----------------After-hoursPre-marketAfter-hoursPre-market----------After-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hours---After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hours--

Key Statistics & Ratios

Market Cap7.45M
Enterprise Value2.18M
Trailing P/E0.00
Forward P/E2.01
PEG Ratio0.71
Price / Sales78.40
Price / Book1.06
EPS-0.71
Book Value0.267
Revenue (TTM)95.00K
Gross Profit (TTM)-22.00K
EBITDA-10.73M
Profit Margin0.00%
Operating Margin-13511.54%
Return on Equity-2382.30%
Return on Assets-82.58%
Shares Outstanding39.18M
Shares Float27.64M
Beta1.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 4.25
  • Strong Buy
    1
  • Buy
    1

Stock Splits

  • Feb 10, 20261031:1000
  • Jun 12, 20251:100
  • Jun 11, 20191:44
  • Aug 29, 20161:12